| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $3.1M | — | +0.6% |
| SG&A Expense | $2.2M | — | -15.6% |
| Operating Income | -$5.2M | — | +6.8% |
| Net Income | -$5.8M | — | -6.1% |
| EPS (Basic) | -$0.19 | — | +24.0% |
| EPS (Diluted) | -$0.19 | — | +24.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.4M | +38.3% | -40.2% |
| Current Assets | $5.5M | +26.1% | -34.5% |
| Total Assets | $26.3M | +8.8% | -54.4% |
| Current Liabilities | $13.6M | +120.7% | +128.2% |
| Total Liabilities | $14.7M | +103.0% | +89.7% |
| Stockholders' Equity | $11.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.4M | — | +44.6% |
| Financing Cash Flow | $4.7M | — | +530.6% |
| -76.8% |